NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reaffirmed at D. Boral Capital

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $34.00 price objective on the stock.

Several other research analysts also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Zacks Research upgraded NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th. Ascendiant Capital Markets raised their price target on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, NRx Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $34.75.

NRx Pharmaceuticals Trading Up 3.1%

Shares of NRx Pharmaceuticals stock traded up $0.08 during mid-day trading on Tuesday, hitting $2.47. 244,367 shares of the stock were exchanged, compared to its average volume of 489,283. The stock has a market capitalization of $69.26 million, a price-to-earnings ratio of -1.04 and a beta of 1.76. NRx Pharmaceuticals has a twelve month low of $1.15 and a twelve month high of $6.01. The company has a 50-day simple moving average of $2.86 and a 200 day simple moving average of $2.89.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The firm had revenue of $0.24 million for the quarter, compared to analyst estimates of $6.83 million. Equities research analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several institutional investors have recently bought and sold shares of NRXP. Anson Funds Management LP increased its position in shares of NRx Pharmaceuticals by 535.1% in the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after acquiring an additional 993,401 shares in the last quarter. Geode Capital Management LLC boosted its position in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after purchasing an additional 37,598 shares during the period. Ethos Financial Group LLC purchased a new stake in NRx Pharmaceuticals during the 3rd quarter worth $39,000. One Wealth Management Investment & Advisory Services LLC increased its holdings in NRx Pharmaceuticals by 86.1% in the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its position in NRx Pharmaceuticals by 29.7% in the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares during the period. 4.27% of the stock is currently owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.